CAS: 1443-42-1; (4-Methylpyridin-3-yl)Methanamine

相似化合物

97004-05-2 98489-36-2 3246-57-9

上下游产品

CAS号7250-52-4 4-甲基烟酰胺

📜3-氰基-4-甲基吡啶置于甲醇,Sodium Tetrahydroborate,Cobalt(II) Chloride Hexahydrate体系中,化学反应 1.0H,以820 Mg的收率获得(4-甲基吡啶-3-基)甲胺
参考文献: Heterocyclic Compound And Use Thereof[fr] Composé Hétérocyclique Et Son Utilisation
标题: Heterocyclic Compound And Use Thereof[fr] Composé Hétérocyclique Et Son Utilisation
摘要:提供了一种杂环化合物,可以对含有nr2B亚基的nmda受体产生拮抗作用,预计可用作预防或治疗抑郁症,双相情感障碍,偏头痛,疼痛,痴呆外周症状等的药物.一种由式(I)表示的化合物,其中每个符号如描述中所定义,或其盐.

专利信息

专利号:US-2023104823-A1
优先权日:2020-01-22
标 题:Process for the preparation of purine derivatives exhibiting cdk inhibitory activity
发明人：SKEAD BENJAMIN; LONDESBROUGH DEREK; GILL CHRIS; HUDSON ALEX
权利人:CYCLACEL LTD
摘要:The present invention relates to a process for preparing a compound of formula [I], or a pharmaceutically acceptable salt thereof, said process comprising the steps of: (i) forming a reaction mixture comprising a compound of formula [II] and a compound of formula [III]; (ii) heating said reaction mixture to a temperature of at least about 130° C. to form a compound of formula [I]; (iii) isolating said compound of formula [I] from the mixture and optionally recovering unreacted compound of formula [III]; and (iv) optionally converting said compound of formula [I] into salt form; wherein: R1 and R2 are each independently H, alkyl or haloalkyl; R3 and R4 are each independently H, alkyl, haloalkyl or aryl; R5 is alkyl, alkenyl, cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR9; R7, R8 and each R9 are independently H, alkyl or haloalkyl, wherein at least one of R7, R8 and R9 is other than H. Further aspects of the invention relate to a process for preparing intermediates of formula [II], and other intermediates useful in the synthesis of compounds of formula [I].

专利号:US-7179918-B2
优先权日:2001-06-11
标 题:HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
发明人：CANAN KOCH STACIE S; ALEXANDER THERESE N; BURKE BENJAMIN J; JEWELL TANYA M; KUCERA DAVID J; LINTON MARIA ANGELICA; MITCHELL JR LENNERT J; REICH SIEGFRIED H; SKALITZKY DONALD J; TATLOCK JOHN H; VARNEY MICHAEL D; VIRGIL SCOTT C; WEBBER STEPHEN E; WORLAND STEPHEN T; BARVIAN MARK; BOLTON GARY; BOYER JR FREDERICK EARL; MACHAK JEFFREY J; HOLLER TOD; MURPHY SEAN T; MELNICK MICHAEL; JOSYULA VARA PRASAD
权利人:AGOURON PHARMA
摘要:Compounds of the formula: n nwhere the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.

专利号:US-7094909-B2
优先权日:2001-06-11
标 题 :HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
发明人：KUCERA DAVID JOHN; SCOTT ROBERT WILLIAM
权利人:AGOURON PHARMA
摘要:The present invention concerns processes for preparing compounds of formula (I-H), or a prodrug, pharmaceutically active metabolite, or pharmaceutically active salt or solvate thereof, n nwhich are useful as inhibitors of the HIV protease enzyme.